Vaccines Against Malaria

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2014 Dec 3

PMID 25452593

Citations 42

Authors

Amed Ouattara

Matthew B Laurens

Affiliations

Soon will be listed here.

Abstract

Despite global efforts to control malaria, the illness remains a significant public health threat. Currently, there is no licensed vaccine against malaria, but an efficacious vaccine would represent an important public health tool for successful malaria elimination. Malaria vaccine development continues to be hindered by a poor understanding of antimalarial immunity, a lack of an immune correlate of protection, and the genetic diversity of malaria parasites. Current vaccine development efforts largely target Plasmodium falciparum parasites in the pre-erythrocytic and erythrocytic stages, with some research on transmission-blocking vaccines against asexual stages and vaccines against pregnancy-associated malaria. The leading pre-erythrocytic vaccine candidate is RTS,S, and early results of ongoing Phase 3 testing show overall efficacy of 46% against clinical malaria. The next steps for malaria vaccine development will focus on the design of a product that is efficacious against the highly diverse strains of malaria and the identification of a correlate of protection against disease.

Citing Articles

Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials.

Ouedraogo A, Ouattara D, Ouattara S, Diarra A, Badoum E, Hema A Malar J. 2024; 23(1):377.

PMID: 39695728 PMC: 11656655. DOI: 10.1186/s12936-024-05198-1.

Community awareness, knowledge and perception about malaria vaccine in the Kassena-Nankana East Municipality: A descriptive cross-sectional survey.

Mohammed A, Bam V, Armah J, Kusi-Amponsah Diji A, Lomotey A, Poku C Nurs Open. 2024; 11(9):e70025.

PMID: 39223744 PMC: 11369012. DOI: 10.1002/nop2.70025.

Hepatocytes and the art of killing Plasmodium softly.

Marques-da-Silva C, Schmidt-Silva C, Kurup S Trends Parasitol. 2024; 40(6):466-476.

PMID: 38714463 PMC: 11156546. DOI: 10.1016/j.pt.2024.04.004.

Cross-reactivity of r48/45, a recombinant protein, with sera from endemic areas of Africa.

Balam S, Miura K, Ayadi I, Konate D, Incandela N, Agnolon V bioRxiv. 2024; .

PMID: 38659832 PMC: 11042229. DOI: 10.1101/2024.04.10.588966.

High genetic and haplotype diversity in vaccine candidate but not among malaria-infected children in Ibadan, Nigeria.

Oboh M, Asmorom N, Falade C, Ojurongbe O, Thomas B PeerJ. 2023; 11:e16519.

PMID: 38099304 PMC: 10720411. DOI: 10.7717/peerj.16519.

References

Wu Y, Ellis R, Shaffer D, Fontes E, Malkin E, Mahanty S . Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One. 2008; 3(7):e2636. PMC: 2440546. DOI: 10.1371/journal.pone.0002636. View

Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Lumeka Kabwende A . A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367(24):2284-95. PMC: 10915853. DOI: 10.1056/NEJMoa1208394. View

Iriemenam N, Khirelsied A, Nasr A, ElGhazali G, Giha H, Elhassan A-Elgadir T . Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine. 2008; 27(1):62-71. DOI: 10.1016/j.vaccine.2008.10.025. View

Greenwood B, Targett G . Do we still need a malaria vaccine?. Parasite Immunol. 2009; 31(9):582-6. DOI: 10.1111/j.1365-3024.2009.01140.x. View

Malkin E, Durbin A, Diemert D, Sattabongkot J, Wu Y, Miura K . Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005; 23(24):3131-8. PMC: 10994215. DOI: 10.1016/j.vaccine.2004.12.019. View

Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, Fegan G . Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One. 2007; 2(8):e707. PMC: 1940326. DOI: 10.1371/journal.pone.0000707. View

Dame J, Williams J, McCutchan T, Weber J, Wirtz R, Hockmeyer W . Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984; 225(4662):593-9. DOI: 10.1126/science.6204383. View

Laurens M, Duncan C, Epstein J, Hill A, Komisar J, Lyke K . A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine. 2012; 30(36):5302-4. DOI: 10.1016/j.vaccine.2012.04.088. View

Kester K, Cummings J, Ofori-Anyinam O, Ockenhouse C, Krzych U, Moris P . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200(3):337-46. DOI: 10.1086/600120. View

10.

. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014; 11(7):e1001685. PMC: 4114488. DOI: 10.1371/journal.pmed.1001685. View

11.

. A research agenda for malaria eradication: vaccines. PLoS Med. 2011; 8(1):e1000398. PMC: 3026701. DOI: 10.1371/journal.pmed.1000398. View

12.

Matuschewski K, Mueller A . Vaccines against malaria - an update. FEBS J. 2007; 274(18):4680-7. DOI: 10.1111/j.1742-4658.2007.05998.x. View

13.

Alloueche A, Milligan P, Conway D, Pinder M, Bojang K, Doherty T . Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg. 2003; 68(1):97-101. View

14.

Miller L, Baruch D, Marsh K, Doumbo O . The pathogenic basis of malaria. Nature. 2002; 415(6872):673-9. DOI: 10.1038/415673a. View

15.

Mackintosh C, Beeson J, Marsh K . Clinical features and pathogenesis of severe malaria. Trends Parasitol. 2004; 20(12):597-603. DOI: 10.1016/j.pt.2004.09.006. View

16.

Gandhi K, Thera M, Coulibaly D, Traore K, Guindo A, Doumbo O . Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg. 2012; 86(5):775-81. PMC: 3335679. DOI: 10.4269/ajtmh.2012.11-0478. View

17.

McCall M, Roestenberg M, Ploemen I, Teirlinck A, Hopman J, de Mast Q . Memory-like IFN-γ response by NK cells following malaria infection reveals the crucial role of T cells in NK cell activation by P. falciparum. Eur J Immunol. 2010; 40(12):3472-7. DOI: 10.1002/eji.201040587. View

18.

Polley S, Tetteh K, Lloyd J, Akpogheneta O, Greenwood B, Bojang K . Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis. 2006; 195(2):279-87. DOI: 10.1086/509806. View

19.

Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I . Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. DOI: 10.1126/science.1241800. View

20.

Thera M, Doumbo O, Coulibaly D, Laurens M, Ouattara A, Kone A . A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011; 365(11):1004-13. PMC: 3242358. DOI: 10.1056/NEJMoa1008115. View